CA2011008A1 - Variants du facteur de croissance epidermique et leur utilisation pharmacologique - Google Patents

Variants du facteur de croissance epidermique et leur utilisation pharmacologique

Info

Publication number
CA2011008A1
CA2011008A1 CA2011008A CA2011008A CA2011008A1 CA 2011008 A1 CA2011008 A1 CA 2011008A1 CA 2011008 A CA2011008 A CA 2011008A CA 2011008 A CA2011008 A CA 2011008A CA 2011008 A1 CA2011008 A1 CA 2011008A1
Authority
CA
Canada
Prior art keywords
egf
variants
pharmaceutical use
egf variants
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2011008A
Other languages
English (en)
Other versions
CA2011008C (fr
Inventor
Zimin Guo
A. Michael Sills
Nigel A. Skipper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allelix Biopharmaceuticals Inc
Original Assignee
Allelix Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharmaceuticals Inc filed Critical Allelix Biopharmaceuticals Inc
Publication of CA2011008A1 publication Critical patent/CA2011008A1/fr
Application granted granted Critical
Publication of CA2011008C publication Critical patent/CA2011008C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002011008A 1989-03-01 1990-02-27 Variants du facteur de croissance epidermique et leur utilisation pharmacologique Expired - Fee Related CA2011008C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US317,467 1989-03-01
US07/317,467 US5218093A (en) 1989-03-01 1989-03-01 EGF variants and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
CA2011008A1 true CA2011008A1 (fr) 1990-09-01
CA2011008C CA2011008C (fr) 1997-09-16

Family

ID=23233788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002011008A Expired - Fee Related CA2011008C (fr) 1989-03-01 1990-02-27 Variants du facteur de croissance epidermique et leur utilisation pharmacologique

Country Status (2)

Country Link
US (1) US5218093A (fr)
CA (1) CA2011008C (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
AU5433701A (en) * 1995-06-07 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Agonist peptide dimers
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6265204B1 (en) 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
AU2001279073B2 (en) 2000-07-28 2006-08-24 Christopher J. Murphy Transplant media
JP2006512891A (ja) * 2002-04-18 2006-04-20 ジェネンコー・インターナショナル・インク 糸状菌における機能性抗体の生産
CA2427190A1 (fr) * 2002-04-30 2003-10-30 Alberta Research Council Inc. Production du facteur de croissance epidermique recombinant dans les plantes
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
US8207118B2 (en) 2009-07-17 2012-06-26 University Of Southern California Skin wound healing compositions and methods of use thereof
WO2011119836A1 (fr) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Procédés et compositions pour la cardioprotection et la régénération cardiaque

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
NO158880C (no) * 1977-11-08 1988-11-09 Genentech Inc Fremgangsmaate for fremstilling av et spesifikt pattedyrhormon.
US4764593A (en) * 1983-04-25 1988-08-16 Amgen Inc. Manufacture and expression of genes for urogastrone and polypeptide analogs thereof
CA1213537A (fr) * 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Methode d'expression de polypeptides
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors

Also Published As

Publication number Publication date
CA2011008C (fr) 1997-09-16
US5218093A (en) 1993-06-08

Similar Documents

Publication Publication Date Title
AU6701890A (en) Process for the production of biologically active protein
CA2011008A1 (fr) Variants du facteur de croissance epidermique et leur utilisation pharmacologique
CA2009735A1 (fr) Composes nitro actifs comme insecticides
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
CA2009579A1 (fr) Analogues de l'insuline
CA2126091A1 (fr) Nouveaux polypeptides biologiquement actifs, leur preparation et composition pharmaceutique les contenant
AU1208588A (en) Muteins of basic fibroblast growth factor, recombinant DNA therefor and it's use
CA2066618A1 (fr) Plasmides renfermant de l'adn encodant la sequence d'acides amines du tcf-ii, cellules transformees a l'aide des plasmides et methode de production de substances biologiquement actives a l'aide des cellules transformees
CA2079342A1 (fr) Composes pharmaceutiques multifonctionnels, leur methode de fabrication et leurs utilisations
FI885807L (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
CA2189947A1 (fr) Utilisation du facteur de von willebrand et formulation pharmaceutique
IT1238348B (it) Processo per la preparazione di costrutti genetici per l'espressione del fattore di crescita nervoso in cellule eucariote.
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
CA2071907A1 (fr) Proteines bcrf1 utilisees comme inhibiteurs de l'interferon-a
CA2025070A1 (fr) Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique
CA2094275A1 (fr) Methodes et compositions pour le traitement de maladies cytoproliferatives
DE69434997D1 (de) Menschliches Chondromodulin-I-Protein
EP0166302A3 (fr) 1-[Bis-(4-fluorophényl)méthyl]-4-(3-phényl-2-propényl)-hexahydro-1H-1,4-diazépine, sa préparation et composition la contenant
EP0739901A3 (fr) Dérivés d'oligoribonucléotides et leur application comme agents antiviraux
CA2118498A1 (fr) Nouvelle cytokine antineoplasique
CA2075926A1 (fr) Esters d'acides amines et d'hydroquinone, methodes d'obtention et compositions phramaceutiques ou cosmetiques qui en contiennent
CA2027075A1 (fr) Muteine de hst-1 et sa production
CA2080008A1 (fr) Muteine hydrosoluble du recepteur de facteur de croissance des fibrolastes
EP0492478A3 (en) Tert-butyloxycarbonyl-l-tyrosyl-peptidoglycan monomer and 125 i-labelled derivative thereof, their preparation and use
CA2099497A1 (fr) Peptides possedant une activite anticoagulante

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed